Breaking News

Aptuit Appoints CEO

December 2, 2013

Goldman to establish new partnerships and pursue strategic acquisitions

Jonathan Goldman, M.D. has been appointed chief executive officer of Aptuit LLC. Dr. Goldman will focus his efforts on the growth of early development services by establishing new partnerships and pursuing strategic acquisitions. He joins the company from ICON Clinical Research, where he served as executive vice president, global strategic and business development and a member of the senior leadership team.
While at ICON, his accomplishments included record growth levels of sales, and the development of business relationships with leading pharma and biopharma companies. Previously, he served as ICON’s executive vice president, operations, strategic programs and chief medical officer, ICON Medical Imaging. Before ICON, Dr. Goldman served as chief medical officer of POINT Biomedical for seven years. He also held honorary academic positions of increasing responsibility at the University of California, most recently as associate Clinical Professor of Medicine in the Division of Cardiology. 
Timothy C. Tyson, chairman of Aptuit, said, "We're enthusiastic that Jonathan is joining us. He brings exceptional experience in science, sales and medicine, along with the innate talents that are needed to advance us to the next level of growth and accomplishments. His collaborative approach to understanding and satisfying the unmet needs of our clients makes him the perfect complement to our senior management team."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important